Company: BIAF
Filing Date: 2025-11-07
Form Type: DEF 14A
Source: 0001493152-25-021269
Chunk: 31

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-07
Form: DEF 14A
Chunk 31
---
 offering, some of the shares we sell could be purchased by one or more investors who could acquire a large block of our common stock. This would concentrate voting power in the hands of a few stockholders who could exercise greater influence on our operations or the outcome of matters put to a vote of stockholders in the future.

We cannot determine what the actual net proceeds of the offerings will be until they are completed, but as discussed above, the aggregate dollar amount of the non-public offerings will be no more than $10 million. If all or part of the offerings is completed, the net proceeds will be used for general corporate purposes, including our strategic M&A initiatives. We currently have no arrangements or understandings regarding any specific transaction with investors, so we cannot predict whether we will be successful should we seek to raise capital through any offerings.

Financial Statements and Supplementary Data

The full text of our audited consolidated financial statements as of December 31, 2024 and 2023 and the interim unaudited financial statements as of March 31, 2025 June 30, 2025 are incorporated by reference to our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 accompanying this Proxy Statement and Quarterly Reports on Form 10-Q for each of the fiscal quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on March 31, 2025, May 15, 2025 and August 14, 2025, respectively.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

For “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for the year ended December 31, 2024 and 2023, please see Item 7 in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 31, 2025 and accompanying this Proxy Statement, which is incorporated herein by reference.

For “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for the three months ended March 31, 2025 and 2024 and the six months ended June 30, 2025 and 2024, please see Item 2 in our quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on May 15, 2025 and August 14, 2025, respectively